Seeing Is Believing
Currently out of the existing stock ratings of Eric Schmidt, 27 are a BUY (100%).
Analyst Eric Schmidt, currently employed at CANTOR FITZGERALD, carries an average stock price target met ratio of 45% that have a potential upside of 26.75% achieved within 818 days.
Eric Schmidt’s has documented 54 price targets and ratings displayed on 12 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on RNA, Avidity Biosciences at 16-Sep-2024.
Analyst best performing recommendations are on BIIB (BIOGEN).
The best stock recommendation documented was for BIIB (BIOGEN) at 1/2/2018. The price target of $338 was fulfilled within 1 day with a profit of $3.83 (1.15%) receiving and performance score of 11.46.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$169
$43.19 (34.33%)
$207
17 days ago
(07-May-2025)
23/35 (65.71%)
$51.79 (44.19%)
130
Hold
$175
$49.19 (39.10%)
$210
19 days ago
(05-May-2025)
1/4 (25%)
$53.2 (43.68%)
26
Buy
$205
$79.19 (62.94%)
$225
22 days ago
(02-May-2025)
39/66 (59.09%)
$81.47 (65.95%)
121
Buy
$255
$129.19 (102.69%)
$300
22 days ago
(02-May-2025)
21/30 (70%)
$131.47 (106.43%)
200
Buy
$187
$61.19 (48.64%)
$300
22 days ago
(02-May-2025)
9/21 (42.86%)
$63.47 (51.38%)
260
What Year was the first public recommendation made by Eric Schmidt?